Skip to Content

Myriad Genetics, Inc. 

Securities Class Action

  • Date:
  • 8/7/2026
  • Company Name:
  • Myriad Genetics, Inc.
  • Stock Symbol:
  • MYGN
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ:MYGN) on behalf of Myriad stockholders. Our investigation concerns whether Myriad has violated the federal securities laws and/or engaged in other unlawful business practices.

On July 30, 2026, Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million, down roughly 11% year-over-year and 7% to 8% below Wall Street consensus of approximately $206-$208 million. Simultaneously, the Company cut its full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million, lowered gross margin expectations, and suspended its adjusted EBITDA guidance entirely - which had previously been set at $37-$49 million. Management attributed the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance. Following this news, Myriad's stock price dropped. Notably, as recently as May 5, 2026, the Company had reiterated its full-year 2026 revenue guidance of $860-$880 million - a range that was slashed by approximately $90 million at the midpoint just three months later.

If you purchased or otherwise acquired Myriad shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Myriad Genetics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: